Stockscreener 앱 받기
5.27
0.35%
0.05
시간 외 거래:
5.26
-0.010
-0.19%
전일 마감가:
$5.22
열려 있는:
$5.15
하루 거래량:
683.83K
Relative Volume:
0.72
시가총액:
$318.64M
수익:
$217.78M
순이익/손실:
$-239.55M
주가수익비율:
-1.3015
EPS:
-4.0492
순현금흐름:
$-127.30M
1주 성능:
+4.35%
1개월 성능:
-3.71%
6개월 성능:
-15.51%
1년 성능:
+20.14%
1일 변동 폭
$5.13
$5.335
1주일 범위
$4.849
$5.335
52주 변동 폭
$4.27
$9.94
Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile
명칭
Vanda Pharmaceuticals Inc
전화
202-734-3400
주소
2200 PENNSYLVANIA AVE NW, WASHINGTON
Compare VNDA vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VNDA
Vanda Pharmaceuticals Inc
|
5.27 | 315.62M | 217.78M | -239.55M | -127.30M | -4.0492 |
VRTX
Vertex Pharmaceuticals Inc
|
515.57 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.86 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
986.80 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
211.94 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.66 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-05 | 개시 | Truist | Buy |
| 2025-11-05 | 개시 | B. Riley Securities | Buy |
| 2024-10-31 | 개시 | H.C. Wainwright | Buy |
| 2024-07-11 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-02-25 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-05-12 | 개시 | BofA Securities | Buy |
| 2021-01-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-10-29 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-06-09 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-03-16 | 다운그레이드 | Oppenheimer | Perform → Underperform |
| 2020-03-12 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-11-07 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2019-08-01 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-07-25 | 다운그레이드 | Stifel | Buy → Hold |
| 2018-12-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2018-12-04 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2018-12-04 | 재확인 | Jefferies | Buy |
| 2018-11-08 | 재개 | Jefferies | Buy |
| 2018-09-21 | 재개 | Oppenheimer | Outperform |
| 2018-05-23 | 개시 | Citigroup | Buy |
| 2018-01-19 | 개시 | Seaport Global Securities | Buy |
| 2017-09-14 | 재확인 | Piper Jaffray | Overweight |
| 2017-06-27 | 재개 | Piper Jaffray | Overweight |
| 2017-05-26 | 개시 | H.C. Wainwright | Buy |
| 2017-04-12 | 개시 | Oppenheimer | Outperform |
| 2016-11-09 | 개시 | Aegis Capital | Buy |
| 2016-10-06 | 재개 | Jefferies | Buy |
모두보기
Vanda Pharmaceuticals Inc 주식(VNDA)의 최신 뉴스
Monaco Asset Management SAM Invests $1.35 Million in Vanda Pharmaceuticals Inc. $VNDA - MarketBeat
Vanda Prepares BYSANTI Launch As Patent Protection Extends To 2044 - Pulse 2.0
Vanda Pharma Stock Rises Pre-Market After FDA Accepts Imsidolimab Filing For Rare Skin Disorder - Stocktwits
VNDA Stock Rises After Hours On Commercial Launch Of Motion Sickness Drug - Stocktwits
Vanda Stock Draws Heavy Buzz Ahead Of FDA Verdict On Bysanti For Bipolar, Schizophrenia - Stocktwits
Vanda Pharmaceuticals Stock Price Forecast. Should You Buy VNDA? - StockInvest.us
AQR Capital discloses 5.82% Vanda Pharmaceuticals (VNDA) ownership on 13G - Stock Titan
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Q3 EPS Estimate for Vanda Pharmaceuticals Cut by Analyst - MarketBeat
VNDA Stock Soars 40% Overnight After Bysanti Approval: What’s The Next Catalyst And How Much Upside Remains? - Stocktwits
Why Did Vanda Pharmaceuticals Stock Slide 7% Pre-Market Today? - Stocktwits
VNDA Reiterated by B. Riley Securities -- Price Target Lowered t - GuruFocus
Vanda Pharmaceuticals' (VNDA) Buy Rating Reaffirmed at B. Riley Financial - MarketBeat
B. Riley Adjusts Vanda Pharmaceuticals Price Target to $12 From $17, Maintains Buy Rating - marketscreener.com
H.C. Wainwright cuts Vanda Pharmaceuticals price target to $20 - Investing.com
H.C. Wainwright cuts Vanda Pharmaceuticals price target to $20 By Investing.com - Investing.com Canada
VNDA Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
Vanda Pharmaceuticals Inc (VNDA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Dimensional Fund Advisors LP Lowers Holdings in Vanda Pharmaceuticals Inc. $VNDA - MarketBeat
Vanda Pharmaceuticals Inc (VM4.DU) insider ownership and holdings - Yahoo Finance Australia
Cantor Fitzgerald Maintains Vanda Pharmaceuticals(VNDA.US) With Buy Rating, Maintains Target Price $11 - moomoo.com
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Just Reported Earnings, And Analysts Cut Their Target Price - simplywall.st
Vanda Pharmaceuticals (VNDA) Stock Holds Steady As Losses Deepen - Sahm
Vanda Pharmaceuticals Inc. (VNDA) latest stock news and headlines - Yahoo Finance Singapore
Vanda Posts Wider Q2 Loss as Spending Surges; Revenue Dips 4% on Hetlioz Decline - finance.biggo.com
Vanda Pharmaceuticals Inc. Quarterly Earnings Report - Stock Titan
Vanda Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat
Arrowstreet Capital Limited Partnership Buys New Position in Vanda Pharmaceuticals Inc. $VNDA - MarketBeat
Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results - AOL.com
Vanda Pharmaceuticals Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Earnings call transcript: Vanda misses Q2 2026 estimates as losses widen - Investing.com
Is Vanda Pharmaceuticals (VNDA) Facing Growth Challenges After Q - GuruFocus
Vanda Pharmaceuticals (NASDAQ:VNDA) Releases Quarterly Earnings Results, Misses Expectations By $0.46 EPS - MarketBeat
Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Vanda Pharmaceuticals Inc. Reiterates Revenue Guidance for the Full-Year 2026 - marketscreener.com
Vanda Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
VANDA PHARMACEUTICALS ($VNDA) Releases Q2 2026 Earnings, Stock Rises - Quiver Quantitative
Vanda Pharmaceuticals Q2 loss widens on lower sales, higher costs - TradingView
BRIEF-Vanda Pharmaceuticals Q2 EPS USD -1.04 - TradingView
Vanda Pharmaceuticals Inc expected to post a loss of 59 cents a shareEarnings Preview - TradingView
Vanda investors can hear its Q2 update Aug. 5 at 4:30 p.m. - Stock Titan
Vanda Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data - reveliolabs.com
$5.23 | Vanda Pharmaceuticals Inc. Common Stock (VNDA) Stock Price Today - Binance
Vanda Pharmaceuticals Inc (VNDA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Vanda Pharmaceuticals Inc (VNDA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Vanda Pharmaceuticals Inc (VNDA) Valuation: PE, PB & Fair Value Analysis - TradingKey
VNDA|Vanda Pharmaceuticals Inc|Price:5.280|Chg%:+0.100 - TradingKey
Vanda Pharmaceuticals (VNDA) to Post Earnings on Thursday - MarketBeat
Vanda's NDA Rejection Challenge Can't Be Heard At DC Court - Law360
ETFs Investing in Vanda Pharmaceuticals Inc. Stocks - TradingView
Licensable picture: Vanda Pharmaceuticals Athens OpenDay 5 - reutersconnect.com
Vanda Pharmaceuticals Inc (VNDA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Vanda Pharmaceuticals Inc 주식 (VNDA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Moran Kevin Patrick | SVP, CFO & Treasurer |
Mar 02 '26 |
Sale |
8.27 |
42,442 |
350,821 |
411,380 |
| Wijkstrom Joakim | SVP, Chief Marketing Officer |
Mar 02 '26 |
Sale |
8.27 |
30,800 |
254,590 |
333,469 |
| Polymeropoulos Mihael Hristos | President and CEO |
Mar 02 '26 |
Sale |
8.17 |
156,235 |
1,276,971 |
2,704,496 |
| Birznieks Gunther | SVP, Business Development |
Mar 02 '26 |
Sale |
8.27 |
42,431 |
350,730 |
494,197 |
2.67%
0.04%
자본화:
|
볼륨(24시간):